Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01474785 · ClinicalTrials.gov registry record · Phase 1
RYGB and the Gastric Adipose Axis
A Phase 1 study, sponsored by Vanderbilt University.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT01474785 is a Phase 1 study that has completed, run by Vanderbilt University. The registered enrollment target is 49 participants.
The verdict
NCT01474785, a Phase 1 study, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if interruption in gastric-adipose tissue axis signaling contributes to early improvements in oxidative stress, insulin sensitivity, and inflammation, and to determine if interruption of the stomach in RYGB results in reduction of plasma acylated ghrelin (AG) and in an altered acylated ghrelin:unacylated ghrelin (AG:UAG) ratio which may contribute to decreased oxidative stress and improved insulin sensitivity.
Interventions
- DRUG human ghrelin
- OTHER very low calorie diet
- PROCEDURE Hyperinsulinemic/Euglycemic Clamp
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2012-01 |
| Est. Completion | 2015-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01474785
The ClinicalTrials.gov registry entry for NCT01474785 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which human ghrelin is the first listed.
NCT01474785 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01474785 about?
NCT01474785 is a clinical study titled "RYGB and the Gastric Adipose Axis". The purpose of this study is to determine if interruption in gastric-adipose tissue axis signaling contributes to early improvements in oxidative stress, insulin sensitivity, and inflammation, and to determine if interruption of the stomach in RYGB results in reduction of plasma acylated ghrelin (AG...
What is the current status of trial NCT01474785?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2012-01. Estimated completion is 2015-07.
What interventions are being tested in trial NCT01474785?
The interventions under investigation include: human ghrelin (DRUG), very low calorie diet (OTHER), Hyperinsulinemic/Euglycemic Clamp (PROCEDURE).
Who is sponsoring clinical trial NCT01474785?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.